Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7737845 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL61818 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL542776 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL77969 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL13858690 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL9956415 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL25327994 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL7340365 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL11594630 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 | |
| SCHEMBL625943 | 1.00 | KMT2A (0.36) | KMT2ANISCHCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125184-A1 | TERTIARY AMINE LIPID COMPOUND AND USE THEREOF | 华南理工大学 | 2023-07-06 | — | — | WO | claimed |
| US-10947220-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | SHIFA BIOMEDICAL CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10899748-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | SHIFA BIOMEDICAL CORPORATION (US) | 2021-01-26 | — | — | US | disclosed |
| US-20200262822-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | SHIFA BIOMEDICAL CORPORATION | 2020-08-20 | — | — | US | disclosed |
| US-20190270729-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-09-05 | — | — | US | disclosed |
| EP-2968266-B1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3471714-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | Shifa Biomedical Corporation (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10131637-B2 | Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases | SHIFA BIOMEDICAL CORPORATION (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2018-03-22 | — | — | US | disclosed |
| WO-2017222953-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20160256467-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2016-09-08 | — | — | US | disclosed |
| EP-2968266-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | Shifa Biomedical Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968318-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | Shifa Biomedical Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150374710-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATEMNT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376139-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| WO-2014150395-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014150326-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2288962-A1 | MOLECULAR RESIST COMPOSITIONS, METHODS OF PATTERNING SUBSTRATES USING THE COMPOSITIONS AND PROCESS PRODUCTS PREPARED THEREFROM | Nano Terra Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20090311484-A1 | Molecular Resist Compositions, Methods of Patterning Substrates Using the Compositions and Process Products Prepared Therefrom | NANO TERRA INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009137049-A1 | MOLECULAR RESIST COMPOSITIONS, METHODS OF PATTERNING SUBSTRATES USING THE COMPOSITIONS AND PROCESS PRODUCTS PREPARED THEREFROM | NANO TERRA INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | KMT2A 2090/4885NISCH 3060/4885CA1 4665/4885 |
| US-10131637-B2 | Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases | PCSK9, PCSK7, PCSK6 | KMT2A 433/4885NISCH 3114/4885CA1 3997/4885 |
| US-10899748-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | PCSK9, PCSK6, PCSK7 | KMT2A 2640/4885NISCH 3233/4885CA1 4013/4885 |
| US-20150374710-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATEMNT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | KMT2A 2171/4885NISCH 1523/4885CA1 4700/4885 |
| US-20150376139-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | KMT2A 2090/4885NISCH 3060/4885CA1 4665/4885 |
| US-20200262822-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | PCSK9, PCSK6, PCSK7 | KMT2A 2640/4885NISCH 3233/4885CA1 4013/4885 |
| US-20190270729-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | PCSK9, PCSK6, PCSK7 | KMT2A 2640/4885NISCH 3233/4885CA1 4013/4885 |
| US-20160256467-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | KMT2A 2650/4885NISCH 1404/4885CA1 4659/4885 |
| US-10947220-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | PCSK9, PCSK6, PCSK7 | KMT2A 2640/4885NISCH 3233/4885CA1 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.